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Introducton
Heart disease, comprising ischemic
heart disease and congestive heart failure,
is not only the leading cause of death and
lost life expectancy in most Western coun-
tries but also one of the most important
causes of morbidity and health care
costs.1 After a period of increasing mor-
tality during the 1950s and 1960s, Western
countries have witnessed a dramatic de-
cline of ischemic heart disease mortality
(age-adjusted), with the United States tak-
ing the lead.2 Though the dynamics are not
completely understood, time trends in
known risk factors for ischemic heart dis-
ease (hypertension, cholesterol, smoking)
in Western countries indicate a clear
decline.3-5 Therefore it is reasonable to at-
tribute at least part of this decrease in mor-
tality to a decrease in incidence.
The observed sharp decline in mor-
tality, together with the probable decline
in incidence, leads one to expect a con-
comitant decrease in health care utiliza-
tion. In reality, however, health care pro-
viders all over the Western world are
facing increases in demand. After the in-
troduction of percutaneous transluminal
coronary angioplasties, utilization ofthese
procedures increased almost exponen-
tially, while the growth in utilization of
coronary artery bypass graft surgery
merely slowed.6 Viewed superficially, the
observed increases in demand are incon-
gruent with the supposed decrease in
need.
But is need truly decreasing? Basic
epidemiologic theory teaches us that if
mortality slows faster than incidence,
prevalence will increase. Although the
Framingham Heart Study has shown a
small decline in incidence, a strong in-
crease in prevalence has been observed,
indicative of a survival gain.3 This im-
proved prognosis has been caused partly
by improved risk factor distributions, but
medical therapy has also contributed.7,8
Recently, beta-blocking agents, platelet
aggregation inhibitors, coronary artery
bypass graft surgery, and angiotensine
converting enzyme inhibitors have been
applied in chronic therapy and thrombo-
lytic therapy has been applied in emergen-
cies. All have been proven effective in ran-
domized controlled trials meeting high
standards.-11 If trends in risk factors and
survival remain favorable, the further de-
crease in incidence and mortality of isch-
emic heart disease is likely to be accom-
panied by a continuing increase in
prevalence. In Westem countries, the in-
creased prevalence will be accentuated by
the aging of the baby boom generation
born after World War II. This cohort will
soon reach middle age with its concomi-
tant heart disease risks: the increase in
age-specific prevalence will be accompa-
nied by an increase in sheer size of the
older age groups.
To make a quantitative analysis of
the dynamics of the heart disease epi-
demic, we developed a simulation model
for the most important manifestations of
ischemic heart disease and congestive
heart failure. Available information from
the medical literature was combined with
data obtained from mortality and morbid-
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ity registers. We explored the future of
heart disease morbidity in the Netherlands
in different scenarios.
Methods
Model Stucture
The deterministic state transition
model used divides the population under
study (here the entire Dutch population)
into homogeneous subpopulations called
states, defined by age, sex, and disease
history. Each year, the population "ages"
by 1 year and the states are updated. Tran-
sitions from one state to another are gov-
erned by transition probabilities, ex-
tracted from registries and literature.
Transition probabilities are independent
from the preceding states and depend only
on the current state (Markov chain as-
sumption).12 The structure of the model
resembles the Coronary Heart Disease
Policy Model of Weinstein et al., but we
have excluded cardiac arrest as a preva-
lent state and included congestive heart
failure.13
The morbidity model consists of
three main sectors: the first-month model,
the ischemic heart disease model, and the
congestive heart failure model. Persons
developing heart disease, the rate ofwhich
is dependent on age and sex, move into
the first-month model, which character-
izes the initial event and its immediate se-
quelae during the first 30 days following
the onset of disease. Persons in whom
congestive heart failure forms the first
heart disease event move directly into the
appropriate model. Survivors of the first
30 days enter the ischemic heart disease
model or the congestive heart failure
model that describes the remaining 11
months of the first year and all subsequent
years. Persons with ischemic heart dis-
ease can move into the congestive heart
failure model, but not vice versa. Death
from heart disease is modeled through the
specific transition probabilities of the
model. In all prevalent states, persons are
subjected to an additional risk of death
from all other causes, corrected for heart
disease, that is based on national life ta-
bles.14
The first-month model covers the
month immediately after the initial cardiac
disease event (Figure 1). This event may
be angina pectoris, an acute coronary
event (an acute myocardial infarction or
cardiac arrest), or congestive heart failure.
Persons suffering a first acute coronary
event may die before reaching a health
care facility (deaths before admission).
Once taken into care, they are subjected
to a further death risk (deaths in hospital).
If the person survives the coronary event,
the pump function of the heart may be
permanently impaired. Patients with heart
failure after an acute myocardial infarc-
tion enter the congestive heart failure
model; the others move into the ischemic
heart disease model. Persons with a first
diagnosis of uncomplicated angina pecto-
ris or congestive heart failure proceed to
the ischemic heart disease and congestive
heart failure models, respectively.
On entry, the ischemic heart disease
model distinguishes between angina pec-
toris and acute coronary event states.
Conditional on these states, patients face
possible new events in the 2 to 12 months
after the first incident. These events range
from acute coronary events to coronary
artery bypass grafts to percutaneous
transluminal coronary angioplasties to all
possible combinations of these. Each
combination of events in a state has a
probability ofsudden death from ischemic
heart disease dependent on the current
event, the current state (and therefore the
ischemic heart disease history), and the
patient's age and sex. The patients also
risk heart failure as a sequel of an acute
coronary event ("ACE + CHF" in the
figure) or as a consequence of chronic
ischemic damage; these patients move
into the congestive heart failure model. If
none of the above occurs, patients will
remain in the ischemic heart disease
model.
After this first year, patients remain-
ing in the ischemic heart disease model are
reclassified into four new states, condi-
tional on previous disease history. These
states are described by the presence or
absence of an acute coronary event or an
intervention. These patients face the same
events as in the previous year. At the end
of each subsequent model year, persons
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FIGURE 1-The heart disease model.
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"age" 1 year and are reassigned to states
that reflect their updated history.
Persons with heart failure after an
acute myocardial infarction face a high
risk of dying during the first year.'1 If they
survive the first year, they move to the
congestive heart failure state describing
the subsequent years, where theywill stay
until death; this state is called "chronic"
to distinguish it from the first critical year
following such a complicated infarction.
In these "chronic" years, the model as-
sumes that mortality rates are lower. All
other patients developing heart failure im-
mediately enter the chronic congestive
heart failure state.
Although nonfatal acute coronary
events are possible in the congestive heart
failure state, such events no longer effect
any change in the assigned state. Patients
in the congestive heart failure state face an
annual probability of death due to cardio-
vascular causes that may be classified as
acute myocardial infarction (ICD 410-
411), chronic ischemic heart disease (ICD
412-414), congestive heart failure (ICD
428-429), or stroke (ICED 430-438).16 We
have incorporated stroke as a specific
cause of death because the Framingham
Heart Study showed that, because of
common riskfactors (hypertension and di-
abetes), congestive heart failure is associ-
ated with increased rates of stroke and
death from stroke.17
Incidence and Recurrence Rates
Reliable and recent incidence data on
heart disease are not available in the Neth-
erlands. Incidence figures have been esti-
mated by an iterative nonlinear procedure
from observed numbers of events (acute
myocardial infarctions, ischemic heart
disease deaths, interventions) and exter-
nally estimated transition probabilities.18
In this section we give a brief account of
how they were derived. The transition
probability matrix for a typical age group
(60 through 64 years) is furnished in Table
1. The complete transition matrices and a
more detailed account of references are
available from the authors on request.
Total numbers of admissions for
acute myocardial infarction (ICED 410), to-
tal numbers of hospital deaths, and total
numbers of interventions by age and sex
are available from the nationwide hospital
register.19-22 Patients with symptomatic
infarctions who are not admitted to hos-
pital (6%; in the Netherlands, this group is
limited to the oldest age groups) are add-
ed.23A constant ratio for the probabilityof
dying before hospital admission versus
dying inside the hospital from an acute
coronary event is aSSumed.20,21,24,25
Reported probabilities of recurrent
acute coronary events vary widely, from
2% to 13% and more per year, depending
on age, case mix, and selection crite-
ria.1326-3" We have assumed that ischemic
heart disease patients without congestive
heart failure have a first annual probability
of a recurrent acute coronary event of
0.062. This probability is consistent with
the estimate ofWeinstein et al. of 0.078, in
which patients with congestive heart fail-
ure are included.13,3' Recurrence rates are
strongly age dependent. We assume the
age distribution to be identical to the
known age distribution of a first acute cor-
onary event in the reference population.
First acute coronary events after a history
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of angina pectoris were modeled on the
basis of data derived from the Framing-
ham study, which showed that male pa-
tients with angina pectoris, who have suf-
fered no previous acute myocardial
infarction have a relative risk of0.54 com-
pared with male patients with a previous
acute myocardial infarction.32 Female pa-
tients with angina pectoris have a relative
risk of 0.45 compared with male pa-
tients.32
Patients eligible for coronary artery
bypass graft surgery run a risk for recur-
rent events that is twice as high as that for
patients who are not eligible.31'33-35 Cor-
onary artery bypass graft surgery reduces
hazard rates by 20o.367 Lacking data on
the effectiveness of percutaneous translu-
minal coronary angioplasty, we assumed
the relative risk for recurrent acute coro-
nary events to be 1.5, with a rate reduction
of 10%0.
Intervention Rates
Intervention rates are known to vary
widely from country to country and even
from hospital to hospital.3839 We have
used age- and sex-specific nationwide out-
put data and assumed constant propor-
tional relations between states to estimate
the numbers ofinterventions in each state.
The risk of an intervention after uncom-
plicated angina pectoris vs the risk of an
intervention after an acute coronary event
is 1.4: 35% of patients with a history of an
acute coronary event are potentially eligi-
ble for an intervention, compared with
50% in uncomplicated angina.4041 The
risk of undergoing an intervention in the
first year after an ischeinic heart disease
event vs the risk in subsequent years was
taken tobe 5.42 The annual probabilities of
having a subsequent intervention after a
first intervention are 1.0% (coronary ar-
terybypass graft) and 0.5% (percutaneous
transluminal coronary angioplasty).43 For
every 10 successful percutaneous translu-
minal coronary angioplasties, another 4
are considered tobe unsuccessful because
of restenosis.4" If both a coronary artery
bypass graft and percutaneous translumi-
nal coronary angioplasty occur in the
same year in the same patient, the percu-
taneous transluminal coronary angio-
plasty is ignored.
Heart Failure
Heart failure due to ischemic heart
disease is caused by acute events or by
chronic ischemic damage. Eighteen per-
cent of ischemic heart disease patients
survive an acute myocardial infarction
with irreversible heart failure as a se-
quel.33.34 The distribution by age, sex, and
previous ischemic heart disease history is
assumed to be the same as the distnbution
of in-hospital mortality by age, sex, and
previous ischemic heart disease history af-
ter an acute myocardial infarction. The an-
nual probabilities of developing conges-
tive heart failure, given a history of
ischemic heart disease, were estimated
from the Framingham Heart Study data.17
We obtained the published annual event
rates of 1.5% given an uncomplicated an-
gina pectoris history and 3.0%o given a his-
tory of an acute coronary event and
adjusted to allow for the number of acute
cases caused by an acute coronary event.
The age distribution was calculated by ap-
plying relative risks of 3.0 (angina pecto-
ris) and 5.0 (acute myocardial infarction)
to the age-specific incidence data taken
from the Framingham study.17
The incidence rates of congestive
heart failure for persons without a history
ofischemic heart disease are calculated by
assuming that persons in whom conges-
tive heart failure is the certified cause of
death survived their first diagnosis of con-
gestive heart failure for 5 (males) to 7 (fe-
males) years.11,12,1517
Heart Disease Mortalit
The total age- and sex-specific in-
hospital mortality rates following acute
coronary events and interventions are
known in the Netherlands.20- The rela-
tive risk of dying after a subsequent vs a
first acute coronary event was taken to be
1.5.132.845 Publications are available in
which the figures on mortality due to a
subsequent vs a first coronary artery by-
pass graft operation are given.46 The rel-
ative risk of death due to percutaneous
transluminal coronary angioplasty vs cor-
onary artery bypass graft surgery is
0.5.47,48 Procedural mortality due to a sub-
sequent or a first percutaneous translumi-
nal coronary angioplasty is taken to be the
same.
The risk of death during the first year
after acute myocardial infarction followed
by congestive heart failure was assumed
to be 25%; the distribution by age was
constructed by exponential interpolation
and extrapolation of data taken from
Ahnve et al.34 The annual mortality risk of
heart failure during the subsequent years
is assumed to be constant: 10%o for fe-
males and 13% for males.15,17,33,34 Of all
deaths caused directly or indirectly by
heart failure, 25% (female) and 37% (male)
are attributable to recurring ischemic
heart events and another 25% (males) and
35% (females) are attnbutable to stroke
(and hence to noncardiac disease).17 The
figures for nonfatal acute coronary events
in persons with heart failure are estimated
by assuming a case fatality of 60%.
All persons in all states are subject to
the risk of dying of other diseases,
adjusted to allow for the causes of death
under study and based on Dutch life ta-
bles.
Resuds
Calculated Estimates for 1985
Figure 2 shows the observed and sim-
ulated events of acute myocardial infarc-
tion: total admissions and deaths in and
outside the hospital, by age and sex. The
model closely reproduces the observed
data. The gap between simulated and ob-
served rates in the older age groups rep-
resents persons with recognized acute
myocardial infarctionswho are not admit-
ted to a hospital. Calculated prevalences
of heart disease by age and sex are shown
in Figure 3. Heart disease is more concen-
trated in the oldest age groups in women,
whereas the burden of morbidity in the
male population is already high at middle
age. The leveling off and decrease by age
in the prevalence ofclinical ischemic heart
disease in men shown in the figure is
causedby the steep rise in the incidence of
congestive heart failure and sudden car-
diac death, reducing clinical ischemic
heart disease incidence. Prevalence of all
heart disease reaches 25% in the age
groups 70 through 74 years (men) and 80
through 84 years (women). Women suffer
relatively more often than men from an-
gina pectoris and congestive heart failure,
but less often from severe ischemic heart
disease. This pattern has been confirmed
time and again in many surveys.32'49'3X
Projections for 1985-2010
Disease-specific mortality is the di-
rect result of incidence and survival. If
two ofthese elements are known, the third
can be calculated. Because the decline in
ischemic heart disease mortality that has
been observed since 1975 is indisputable,
we postulated an ongoing decline of this
mortality into the near future. We provide
three plausible scenarios, based on vary-
ing assumptions of further decreasing in-
cidence rates and improving prognoses
(see Table 2).
The reference scenario, based on the
Framingham Heart Study, supposes that
one third of the mortality decline is ex-
plained by a decline in incidence (-1.0%
per year) and that two thirds is explained
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by an increase in survival.3,4,8.9,26,51 In an
extreme low-incidence-change scenario,
we assume that the incidence decrease is
even less: -0.5% per year. This is the
magnitude of change predicted by a risk
factor model, based on changes in risk fac-
tor prevalences in the Netherlands.5 In an
extreme high-incidence-change scenario,
we assume a high decrease in incidence
(-1.7% per year).
We have projected these trends over
the period 1985 through 2010 to juxtapose
the effects of demographic and epidemio-
logic change.
The results are summarized in Fig-
ures 4 through 6 and Table 3. Figure 4
shows how the decreasing incidence, to-
gether with the increase in survival, re-
sults in lower prevalence rates in the
young and increasing prevalence rates in
older age groups. In the youngest (30- to
39-year-old) age group, the decrease will
be about 25%; in the oldest old (85 years
and older), prevalence will increase by
20% for men and 10% for women. Super-
imposing the population projections on
these figures results in a completely dif-
ferent picture, which is shown in the same
figure. The movement ofthe postwarbaby
boom generation into middle age and the
sharp increase in the number of the very
elderly is clearly revealed. Together with
the projected increase in prevalence rates,
this demographic change will result in a
steep climb in the number of heart disease
patients in the oldest age groups. Hence,
while epidemiological changes in cardio-
vascular disease will result in an increase
of 10% to 20% in prevalence rates for the
oldest old (85 years and older), the abso-
lute number of patients will more than
double.
Figures 5 and 6 show the projected
changes in age-specific prevalences for
different types of ischemic heart disease;
Figure 5 shows the relative changes in
rates and Figure 6 shows the absolute
changes in numbers. The change in age-
specific rates for all ischemic heart disease
combined is the same as in Figure 4.
Figure 5 shows a relative increase of
severe ischemic heart disease. Milder
stages of the disease act as a risk factor for
the more severe stages. If survival in-
creases in all disease stages, effects will
culminate in the most serious stages: as
more patients stay alive with ischemic
heart disease, more will have the oppor-
tunity to develop congestive heart failure.
Figure 6 shows the changes in absolute
terms: the relative decrease of prevalence
at younger ages has hardly any impact be-
cause of the low number of patients with
24 American Joumal of Public Health
BDonneux etaL
1500-
-~~~~~~~~~~~~~~~1500~
500- 500
o- 0
30 40 50 60 70 80 90 40 50 60 70 80 90
Age
AdmiWios for AMI
DOaths from AMI
Deaths hoispi
Note. "Admissions for AMI" are the rates of patients discharged with a primary diagnosis of
aact myocardial infarcon (ICD 410). "Deaths in hospitl" are the rates of patients with the
same diagnosis dying in hospital.20 "Deatsfrom AMI" are the total rates ofdeathfrom acute
myocardi! infarction (ICD 410).21 The solid lines wth symbols showobserved numbers; the
dotted lines represent the simulaion by the heart disease model.
FIGURE 2-Obseved sImuated event In 1985.
Age
All howl dise
All IHD
IHD without CHF
uncomplicated AP
Note. "Uncomplicated AP" is defined as angina pectoris only, wfthu a history of acute
myocardial inftion. "IHD witou CHF' describes all patients with a hstoxy of ischemic
heart disease but without congestve heart failure. "All IHD" compris all ischemic heart
disease, including pafients who developed congestive heart failure after ischemic heart
disease. "AlI heart disease" summarizes all three conditions. The difference between all
heart disease and all ischemkc heart disease shows the prevalence of congestive heart
failure.
FIGURE 3-Cumuav prevalne of heat d ,ease by age and sex, Xt Nehad,
195. i
January 1994, Vol. 84, No. 1
Heart-Diseas Morbidity
ischemic heart disease at early ages. How-
ever, the combination of aging and in-
creasing survival of heart disease leads to
a flood of middle-aged men with ischemic
heart disease followedby a slowerwave of
elderly persons with heart failure.
Table 3 shows expected changes in
age-standardized rates, using the Euro-
pean Standard Population as the standard,
and in absolute numbers, combining the
rates with the expected population dy-
namics in the Netherlands. The mortality
decline (observed between 1975 and 1990
and projected over the next 20 years) is so
strong that it will be evident even when
expressed in absolute numbers. Although
the assumed decline in incidence of first
myocardial infarctions, which accounts
for one third of the decline in mortality, is
too small to counteract the aging of the
Dutch population, the rate of all myocar-
dial infarctions together will nevertheless
decrease substantially. This decrease is
the result of the combined decline in inci-
dence and recurrence; the better survival,
on the other hand, through which the
number of patients at higher risk of recur-
rent infarctions is increased, is not strong
enough to counteract this decline. Be-
cause more patients will stay alive and at
risk for interventions and reinterventions
andbecause ofthe aging ofthe population,
the need for coronary artery bypass graft
surgery and percutaneous transluminal
coronaiy angioplasty will increase by 1%
per year (range: 0.4%o-1.6%). The age-
standardized prevalence ratios for milder
ischemic heart disease tend to decrease,
but those for ischemic heart disease com-
plicated by congestive heart failure in-
crease strongly: in absolute numbers, a
growth of more than 70%o is to be ex-
pected.
Discussion
Simulation modeling provides quan-
titative insight into epidemiological and
public health dynamics and potential fu-
ture developments. The information
needed for these models can never be sup-
plied by a single data source. Combining
data from different sources is therefore ap-
propriate, and the use of state-transition
models provides a simple and comprehen-
sible means ofdoing so. The methods used
are relatively easy to understand. The pa-
rameters of the model are meaningful to
physicians and the results are interpret-
able by health care providers, who are the
principal users of these results.
Nevertheless, to interpret results cor-
rectly, the limitations of this kind of mod-
eling should be understood. A number of
simplifying assumptions are always nec-
essaxy to keep the model, and more par-
ticularly the number of parameters to be
estimated, manageable. We included cer-
tain disease manifestations and excluded
others. Unlike Weinstein et al., we ex-
cluded cardiac arrest as a prevalent state
but included congestive heart failure. Car-
diac arrest is highly lethal, and no major
error is introduced by mixing the history
of those surviving an acute myocardial in-
farction with that of a few survivors of
cardiac arrest. On the other hand, the in-
clusion of congestive heart failure takes
into account an important cause ofchronic
and severe morbidity. Modeling the dy-
namics of and the relations between these
different types and levels of morbidity
should result in amore realistic estimate of
future health care needs.
We used registered admissions for
acute myocardial infarction (ICD 410),
deaths from ischemic heart disease (ICD
410-414) and congestive heart failure (ICD
428-429), and transition probabilities ex-
tracted from multiple sources to estimate
incidences. This complicates the assess-
ment ofvalidity, which is the most impor-
tant problem of this or any other model
with such complexity. The model output
reflects state-of-the-art clinical evidence,
closely simulating present hospitalization,
intervention, and mortality rates (see Fig-
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ure 2). Its estimated prevalences ofclinical
disease coincide closely with empirical
observationS.49502
Our forecasts are based on mortality
projections. For health care planning pur-
poses, projections of incidence based on
past risk factor prevalences are less reli-
able. First, prevalences of all known risk
factors for heart disease are not available;
prevalence numbers that are available are
often highly inconsistent between studies.
For example, estimates of the prevalence
of hypertension in Dutchmen aged 50
through 59 years vary from 14.4% to
67%.5,52 Second, not all risk factors are
known or observable; projections based
only on known risk factors are bound to
underestimate future trends. The assump-
tion that mortality will continue to decline
is uncertain, but not implausible. It sup-
poses a progressive change in risk factor
distributions, a more widespread use of
effective health care interventions in the
future, and ongoing technological advanc-
es.3 4 8 9 The level of ischemic heart dis-
ease mortality expected in 2010 is compa-
rable to that of 1950 (making allowances
for changes in codification). Given the ab-
sence of effective therapies in 1950, this is
not an extreme result. The reference sce-
nario supposes a decrease in incidence,
explaining one third of the mortality de-
cline, based on the Framingham study.4
Other assumptions about incidence de-
creases and survival increases within ex-
treme ranges are shown in the alternative
26 American Journal of Public Health
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scenarios.3,4,8 These assumptions influ-
ence the absolute magnitude of the ex-
pected changes, but not the direction.
Declining incidence rates mean that
the onset of disease is postponed but not
halted. The delay in occurrence causes a
reduction of morbidity in the young,
which, however, is canceled out with age.
Mortality is deferred to an even greater
extent, owing to a combination of the de-
crease in incidence and improved progno-
sis. This mortality decrease will be traded
off for a steep increase of more severe
morbidity in the old.
Changes in demography will prevent
a decrease ofnew cases ofheart disease.13
However, while age-specific incidence
rates show a decline, acute myocardial in-
farction rates will drop more steeply, ow-
ing to a reduction in both incidence and
recurrence rates; the increasing preva-
lences are insufficient to cancel these re-
ductions. The reference scenario predicts
a decline in acute myocardial infarction
rates that will be sufficiently strong to off-
set population aging; this development has
been observed in the Netherlands since
1985.19-21 But although disease incidence
rates are declining, intervention rates will
remain unchanged, even assuming that in-
tervention rates per group of patients in a
certain disease state remain constant. The
reason is that more patients will survive
and, on average, survival is longer, result-
ing in more people in disease states who
are eligible for invasive coronary revascu-
larization procedures.
The overall picture emerging from
the heart disease scenarios is one of tran-
sition from an acute to a more chronic
disease: event rates are declining steeply,
but the postponed mortality is traded off
for increased morbidity and severity of
disease among the elderly. This pattern
can be observed in hospital admission
rates in the Netherlands, in data from the
National Health Interview Survey in the
United States, and in data from the Na-
tional Health Survey of Japan.19-53 All of
these data show increasing prevalences of
ischemic heart disease. As a consequence,
overall health care needs will continue to
rise, regardless of declining mortality and
incidence.
These calculations, based on empir-
ical observations, shed a new light on
Fries' compression of morbidity theory.54
The compression of morbidity theory
hinges on the proposition that the inci-
dence of disease will be postponed more
rapidly than mortality. For heart disease,
the evidence suggests that the decline of
lethality expands the number of years
January 1994, Vol. 84, No. 1
spent with heart disease morbidity, re-
gardless of the incidence postponement.
Healthy life expectancy is extended, as
expected by Fries and assumed by the
scenarios, but contrary to his prediction,
total life expectancy is extended even
further. Among the middle-aged and el-
derly, acute heart disease lethality in the
Netherlands is high, increasing sharply
with age. Obviously, herewould appear to
be a serious potential for reduction. In
1985, for example, the model calculated
that 41% of the 70-year-old men died
within4weeks oftheir first acute coronary
event.20-24 In our scenarios 32% (range:
30%-34%) are predicted to die within the
same period in the year 2010, which in our
view remains a conservative estimate. Be-
cause heart disease is concentrated in the
older age groups, even small differences in
the rates of change in incidence and mor-
tality can have major consequences, par-
ticularly now that pushing back mortality
has been shown to be counterbalanced by
an increase in the more severe stages of
heart disease. With short-term case-fatal-
ity subsequent to an acute event as high as
it is, lowering these rates will remain an
important goal ofhealth care intervention.
Should this aim be successful, the result-
ing increase in the number of survivors
will boost heart disease morbidity and
lengthen life expectancy with disease.
Only if health care interventions aimed at
reducing mortality subsequent to the
event should prove a waste of time and
money would no expansion of morbidity
be expected. O
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